David V. Gauvin (2016) “Defining ‘Best Practices’ for Critical Endpoints in Preclinical Screening of New Chemical Entities for Ototoxicity Liability”, Otolaryngology, 2(2), pp. 58–69. Available at: https://openventio.us/index.php/OOJ/article/view/2437 (Accessed: 26 August 2026).